Skip to Content

Generic Qvar RediHaler Availability

Qvar RediHaler is a brand name of beclomethasone, approved by the FDA in the following formulation(s):

QVAR REDIHALER (beclomethasone dipropionate - aerosol, metered;inhalation)

  • Manufacturer: NORTON WATERFORD
    Approval date: August 3, 2017
    Strength(s): 0.04MG/INH [RLD], 0.08MG/INH [RLD]

Has a generic version of Qvar RediHaler been approved?

No. There is currently no therapeutically equivalent version of Qvar RediHaler available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qvar RediHaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dose counter for inhaler having a bore and shaft arrangement
    Patent 10,022,509
    Issued: July 17, 2018
    Assignee(s): Ivax Pharmaceuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A dose counter for an inhaler, the dose counter having a display tape arranged to be incrementally driven from a tape stock bobbin onto an incremental tape take-up drive shaft, the bobbin having an internal bore supported by and for rotation about a support shaft, at least one of the bore and support shaft having a protrusion which is resiliently biased into frictional engagement with the other of the bore and support shaft with longitudinally extending mutual frictional interaction.

    Patent expiration dates:

    • May 18, 2031
      Drug product
  • Dose counters for inhalers, inhalers and methods of assembly thereof
    Patent 10,022,510
    Issued: July 17, 2018
    Assignee(s): Ivax Pharmaeuticals Ireland Norton (Waterford) Limited Teva Pharmaceuticals Ireland

    A tape system for a dose counter for an inhaler, the tape system having a main elongate tape structure, dosing indicia located on the main elongate tape structure, tape positioning indicia located on the main elongate tape structure, a tape size marker located on the main elongate tape structure indicating a number of dosing indicia on the tape, and priming indicia located on the main elongate tape structure, the priming indicia being located between the dosing indicia and one end of the tape.

    Patent expiration dates:

    • May 18, 2031
      Drug product
  • Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber
    Patent 7,637,260
    Issued: December 29, 2009
    Inventor(s): Holroyd; Michael
    Assignee(s): Norton Healthcare Limited

    A metered dose inhaler for use with a pressurized aerosol container which is preferably breath-actuated. A preload is applied to the internal aerosol valve by an amount sufficient to result in a dose release, but this is prevented by the application of a pneumatic resisting force. The inhaler comprises a release device which, upon actuation, releases the resisting force and allows the preload to actuate the aerosol valve. A metered dose of medicament is then released for inhalation by the patient. The pneumatic resisting force is established by a negative pressure region defined in part by a diaphragm. The diaphragm includes a central disk of a first, relatively high stiffness material and a peripheral ring, coupled by a flexure of a second, relatively low stiffness material.

    Patent expiration dates:

    • August 25, 2020
      Drug product
  • Metered-dose inhaler
    Patent 8,132,712
    Issued: March 13, 2012
    Inventor(s): Fenlon; Derek
    Assignee(s): Ivax Pharmaceuticals Ireland

    A metered dose inhaler dose counter, the counter includes: an actuator; a rotary gear wheel having a plurality of ratchet teeth; a driver for driving the rotary gear in a step-wise fashion in response to displacement of the actuator; a pawl that prevents reverse rotation of the rotary gear; and a display coupled to the rotary gear.

    Patent expiration dates:

    • September 7, 2028
      Drug product
  • Inhaler
    Patent 8,931,476
    Issued: January 13, 2015
    Assignee(s): IVAX Pharmaceuticals Ireland

    An inhaler, such as a breath-actuated metered-dose inhaler, for delivering medicament to a patient. The inhaler includes a housing for holding the medicament and having an air inlet and a medicament delivery port which together define an air flow path into which the medicament is dispensed. The air inlet includes an array of elongate apertures formed in the housing, the long sides of adjacent apertures facing each other. Each aperture is provided with a respective different opening in an outer surface of the housing. The opening of each aperture extends in two different planes such that, if at least a part of the opening is covered in one of the two different planes during inhalation by the patient, a void space is created between the cover and the aperture so as to provide an air flow path through the void space to the at least one aperture.

    Patent expiration dates:

    • July 17, 2031
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.